medicine-products/vcm-12--complete-1-chip-camera-system--international-12325-1/;msg90356

Breaking Biology Technology:Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery 2 Vivakor Announces Additions to Board of Directors and Scientific Advisory Board 2 Vivakor Announces Additions to Board of Directors and Scientific Advisory Board 3 EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2 Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2 Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3

[0] Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery [0] Vivakor Announces Additions to Board of Directors and Scientific Advisory Board [0] EUCODIS Bioscience Appoints Thomas Fischer as New CEO [0] Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures

Breaking Medicine Technology:Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2 ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2 ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3 ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 1 SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 2 SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 3 SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 4 SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 5 SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 57495 6 African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 1 African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 2 African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 3 African Americans at Significantly Higher Risk of DVT or Blood Clots 57491 4 Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 1 Rigel Announces Pricing of Public Offering of 13 000 000 Shares of Common Stock 14119 2

[0] Royalty Pharma Announces that Alexander von Perfall Joins Management Team [0] ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program [0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology